ASX ANNOUNCEMENT

15 May 2024

First In Human TAVR in TAVR in SAVR using DurAVR™

Anteris Technologies Ltd (ASX: AVR) announces it has successfully performed a difficult to treat "Valve-in-Valve-in-Valve" procedure.

The patient, who was receiving a third valve replacement (or valve-in-valve-in-valve) has been successfully treated at the Karolinska University Hospital in Stockholm, Sweden by Dr Andreas Rück, Dr Magnus Settergren and Dr Nawzad Saleh.

The patient had previously received a surgical valve, which failed after 7 years, and was replaced by inserting a TAVR valve inside the surgical valve 6 years ago but had now failed and led to the patient becoming severely debilitated due to his valve disease and in need of a viable third solution.

The heart team deemed the patient unsuitable (or at extreme risk) for a surgical intervention and that commercially available TAVR devices would not provide meaningful benefit to the patient. The team determined DurAVR™ would offer the only alternative in this case and compassionate use approval was sought, granted and the patient has been successfully treated.

Dr Andreas Rück stated, "We are impressed with the outcome in this very difficult to treat patient. DurAVR™ allowed us to treat a patient who was deemed unsuitable for surgical intervention or in fact other TAVRs. The device was easy to use and allowed us to implant the valve in a predictable way. Further, it has provided the patient with the best functioning valve since before his first valve replacement, this despite it being placed inside two other valves. We were pleased to see that the remarkable performance previously seen in native aortic stenosis and valve-in-valve, even delivers in the challenging valve-in-valve-in-valve cases."

Dr Magnus Settergren further commented "The patient had already had both a surgical valve and a TAVR placed inside the surgical valve in the past years to treat their Aortic Stenosis. Both valves had failed leaving the patient with no alternatives. The DurAVR™ allowed us to get a result no other available valve could offer. It worked well in a challenging environment and the patient is feeling much better. This will be an important valve, not just for native aortic stenosis but also in the complex TAVR in failed surgical valves and failed TAVR valves."

"We are pleased that even in the most challenging settings we are giving patients viable solutions to their disease. The outcome in this difficult to treat setting where other therapies were deemed unsuitable is further testimony to the unique profile of DurAVR™ as a first in class biomimetic valve", said Wayne Paterson, CEO.

Dr Chris Meduri commented, "The impact of Biomimetic technology is seen in a wide variety of patients. We have clearly demonstrated in our clinical trials that in native aortic stenosis patients we are achieving normalized pre-disease hemodynamics as well as normal flow beyond what has been achieved in the past. It is well recognized that Valve-in-valve is a growing phenomenon and estimated that in the near future 30% of the TAVR market will be patients needing a second replacement. The Company is pleased that it is aiming to offer a valuable alternative product for first line treatment, as well as a viable solution for patients who will need a second valve replacement."

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company's lead product, DurAVR™, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR™ THV was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR™ THV is made using ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The ComASUR™ Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR™ THV with balloon-expandable delivery, allowing precise alignment with the heart's native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor Relations
investors@anteristech.com
Anteris Technologies Ltd
+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)
Malini Chatterjee, Ph.D.
Managing Director
Blueprint Life Science Group
+1 917 330 4269

Website	www.anteristech.com
Twitter	@AnterisTech
Facebook	www.facebook.com/AnterisTechnologies
LinkedIn	https://www.linkedin.com/company/anteristech